Body mass index is not associated with survival outcomes and immune-related adverse events in patients with Hodgkin lymphoma treated with the immune checkpoint inhibitor nivolumab

par Rosaria De Filippi, Fortunato Morabito, Armando Santoro, Giovanni Tripepi, Francesco D’Alò, Luigi Rigacci, Francesca Ricci, Emanuela Morelli, Pier Luigi Zinzani, Antonio Pinto
Publié 2021

Risk factors for immune-related adverse events: what have we learned and what lies ahead?

par Xiaoyan Liu, Yuequan Shi, Dongming Zhang, Qing Zhou, Jia Liu, Minjiang Chen, Yan Xu, Jing Zhao, Wei Zhong, Mengzhao Wang
Publié 2021

Correlation between immune-related adverse events and therapeutic effects of nivolumab in patients with malignant pleural mesothelioma

par Hiroto Yoneda, Hiroshi Nokihara, Atsushi Mitsuhashi, Ryohiko Ozaki, Yohei Yabuki, Hirokazu Ogino, Kenji Otsuka, Yasuhiko Nishioka
Publié 2021

Rheumatic Manifestations and Diseases From Immune Checkpoint Inhibitors in Cancer Immunotherapy

par Pan Shen, Xuan Deng, Zhishuo Hu, Zhe Chen, Yao Huang, Ke Wang, Kai Qin, Ying Huang, Xin Ba, Jiahui Yan, Liang Han, Shenghao Tu
Publié 2021

Nivolumab-Induced Exocrine Pancreatic Insufficiency

par Boudewijn Sweep, Sofie Wilgenhof, Sander Anten
Publié 2021

Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A R...

par Morten Fink, Anders Schwartz Vittrup, Lars Bastholt, Inge Marie Svane, Marco Donia, Adam A. Luczak, Christina H. Ruhlmann, Louise Mahncke Guldbrandt, Ulrich Heide Koehler, Mette Lerche Winther, Eva Ellebaek, Charlotte Aaquist Haslund, Henrik Schmidt
Publié 2021

Pan-Cancer Analysis Reveals Alternative Splicing Characteristics Associated With Immune-Related Adverse Events Elicited by Checkpoint Immunotherapy

par Xiujing He, Jing Yu, Hubing Shi
Publié 2021

Endocrine Disorders Induced by PD-1/PD-L1 Inhibitor and Related Treatment

par LAI Yanliang, GENG Yan, YANG Bingquan
Publié 2021

Ipilimumab and Nivolumab induced ventricular tachycardia in a patient with metastatic renal cell carcinoma

par Pramod Savarapu, Basel Abdelazeem, Sakiru Isa, Kavitha Kesari, Arvind Kunadi
Publié 2021

Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events

par Rilan Bai, Naifei Chen, Xiao Chen, Lingyu Li, Wei Song, Wei Li, Yuguang Zhao, Yongfei Zhang, Fujun Han, Zheng Lyu, Jiuwei Cui
Publié 2021

Impact of Immune-Related Adverse Events on Efficacy of Immune Checkpoint Inhibitors in Patients with Advanced Hepatocellular Carcinoma

par Kennedy Yao Yi Ng, Sze Huey Tan, Jack Jie En Tan, Desiree Shu Hui Tay, Ailica Wan Xin Lee, Andrea Jing Shi Ang, Lawrence Wen Jun Wong, Su Pin Choo, David Wai-Meng Tai, Joycelyn Jie Xin Lee
Publié 2021

Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis

par Melissa L. Bastacky, Hong Wang, Dylan Fortman, Zahra Rahman, Gerard P. Mascara, Timothy Brenner, Yana G. Najjar, Yana G. Najjar, Jason J. Luke, Jason J. Luke, John M. Kirkwood, John M. Kirkwood, Hassane M. Zarour, Hassane M. Zarour, Diwakar Davar, Diwakar Davar
Publié 2021

Pembrolizumab-Induced Adrenal Insufficiency in Patients with Untreated Advanced Non-Small Cell Lung Cancer: A Case Series

par Kei Sonehara, Kazunari Tateishi, Taisuke Araki, Masamichi Komatsu, Jumpei Akahane, Hiroshi Yamamoto, Masayuki Hanaoka
Publié 2021

Patterns and outcomes of immune-related adverse events in solid tumor patients treated with immune checkpoint inhibitors in Thailand: a multicenter analysis

par Nuttapong Ngamphaiboon, Suthinee Ithimakin, Teerada Siripoon, Nattaya Sintawichai, Virote Sriuranpong
Publié 2021

Development of a Flow Cytometry Assay to Predict Immune Checkpoint Blockade-Related Complications

par Hannah-Lou Schilling, Gunther Glehr, Michael Kapinsky, Norbert Ahrens, Norbert Ahrens, Paloma Riquelme, Laura Cordero, Florian Bitterer, Hans J. Schlitt, Edward K. Geissler, Sebastian Haferkamp, James A. Hutchinson, Katharina Kronenberg
Publié 2021

Diagnosis and Management of Immunotherapy-related Liver Toxicity

par HUA Yuwei, ZHAO Lin
Publié 2021

Adverse Events Induced by PD-1/PD-L1 Inhibitors: A Real-World Single-Centre Experience with a Management-Based Approach

par Grimaud F, Penaranda G, Stavris C, Retornaz F, Brunel V, Cailleres S, Pegliasco H, Le Treut J, Grisoni V, Coquet E, Chiche L, Rognon A
Publié 2021

Unravelling Checkpoint Inhibitor Associated Autoimmune Diabetes: From Bench to Bedside

par Linda Wu, Linda Wu, Linda Wu, Linda Wu, Venessa H. M. Tsang, Venessa H. M. Tsang, Sarah C. Sasson, Sarah C. Sasson, Sarah C. Sasson, Alexander M. Menzies, Alexander M. Menzies, Alexander M. Menzies, Matteo S. Carlino, Matteo S. Carlino, Matteo S. Carlino, David A. Brown, David A. Brown, David A. Brown, David A. Brown, Roderick Clifton-Bligh, Roderick Clifton-Bligh, Jenny E. Gunton, Jenny E. Gunton, Jenny E. Gunton
Publié 2021

Factors associated with immunotherapy respond and survival in advanced non-small cell lung cancer patients

par Yahua Wu, Haishan Wu, Mingqiang Lin, Tianxiu Liu, Jiancheng Li
Publié 2022

The Continuum of Thyroid Disorders Related to Immune Checkpoint Inhibitors: Still Many Pending Queries

par Maria V. Deligiorgi, Sofia Sagredou, Lampros Vakkas, Dimitrios T. Trafalis
Publié 2021